Definitive Healthcare (NASDAQ:DH) Price Target Lowered to $9.50 at Stifel Nicolaus

Definitive Healthcare (NASDAQ:DH) had its price target lowered by Stifel Nicolaus from $11.00 to $9.50 in a report issued on Wednesday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other research analysts also recently weighed in on the stock. Barclays increased their price objective on shares of Definitive Healthcare from $10.00 to $11.00 and gave the company an equal weight rating in a research report on Friday, March 1st. Morgan Stanley downgraded shares of Definitive Healthcare from an overweight rating to an equal weight rating and dropped their price objective for the stock from $11.50 to $9.00 in a report on Wednesday. Needham & Company LLC reissued a hold rating on shares of Definitive Healthcare in a report on Wednesday. Finally, Canaccord Genuity Group increased their target price on shares of Definitive Healthcare from $9.00 to $10.00 and gave the stock a hold rating in a report on Thursday, February 29th. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Definitive Healthcare has an average rating of Hold and a consensus target price of $10.81.

Definitive Healthcare Price Performance

Shares of NASDAQ DH remained flat at $5.35 during trading on Wednesday. The stock had a trading volume of 390,337 shares, compared to its average volume of 608,925. The stock has a market cap of $630.18 million, a PE ratio of -3.01, a PEG ratio of 6.12 and a beta of 1.41. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.31 and a current ratio of 2.31. Definitive Healthcare has a 52-week low of $4.38 and a 52-week high of $12.45. The business’s 50-day moving average is $7.70 and its 200-day moving average is $8.29.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.02). Definitive Healthcare had a negative net margin of 80.40% and a positive return on equity of 0.43%. The business had revenue of $65.93 million for the quarter, compared to analysts’ expectations of $66.01 million. On average, analysts anticipate that Definitive Healthcare will post 0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC raised its position in shares of Definitive Healthcare by 599.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock worth $58,000 after acquiring an additional 4,959 shares in the last quarter. Norden Group LLC purchased a new stake in shares of Definitive Healthcare during the first quarter valued at about $83,000. Berry Wealth Group LP bought a new stake in shares of Definitive Healthcare in the 1st quarter valued at about $99,000. SG Americas Securities LLC purchased a new position in shares of Definitive Healthcare in the 3rd quarter worth approximately $116,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Definitive Healthcare during the 1st quarter worth approximately $120,000. 98.67% of the stock is currently owned by institutional investors.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.